FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Dr. Gupta details new FDA-approved pain medication with no opioids
The US Food and Drug Administration signed off on the first new type of pain reliever to be approved in more than two decades ...
Cure Today11h
FDA-Approved Calquence Combo Is First and Only of Its Kind in MCL
Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...
FDA approves opioid-free pain medication with 'no sign of addiction'
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.
FDA approves pig organ transplant trials for patients with kidney failure
The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...
healthday7h
FDA Approves Susvimo for Diabetic Macular Edema
Susvimo is the first and only FDA-approved treatment shown to maintain vision in people with diabetic macular edema with ...
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
Going forward, we may see more instances in which insurers deny or (temporarily) severely restrict coverage of accelerated ...
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
Interesting Engineering on MSN20h
US FDA approves first-ever smart glasses with hearing aid for mild to moderate loss
EssilorLuxottica's Nuance Audio Glasses receive FDA clearance for OTC sales in the US, revolutionizing hearing solutions with ...
Business Wire1d
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...